News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Boehringer Ingelheim Corporation and Eli Lilly and Company Release: Phase III Safety and Efficacy Data of Trajenta® (linagliptin) in Elderly People With Type 2 Diabetes Published in The Lancet
August 15, 2013
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Get the latest biotech news where you want it. Sign up for the
free GenePool newsletter
today!
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Europe
Eli Lilly and Company
Boehringer Ingelheim
MORE ON THIS TOPIC
Business
“Perfect Patient” Industry Burdens; Exits and Investment in Women’s Health
March 13, 2025
·
1 min read
·
Lori Ellis
Autoimmune disease
Amgen’s Uplizna Deepens Response Against Myasthenia Gravis at 1 Year
March 13, 2025
·
1 min read
·
Tristan Manalac
Infectious disease
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
March 12, 2025
·
2 min read
·
Tristan Manalac
Breast cancer
Pfizer, Arvinas Post Mixed Late-Stage Breast Cancer Data for Closely Watched PROTAC Drug
March 11, 2025
·
2 min read
·
Tristan Manalac
